Infliximab is a chimeric IgG1 monoclonal antibody that binds to human TNF and which, via intracerebroventricular delivery in mouse AD models, decreases TNF levels, hyperphosphorylated tau, and Aβ plaque burden [321]. Here, MAPT is linked to Alzheimer disease.